HDAC (Histone Deacetylases) are a group of enzymes that allow histones to more tightly wrap the DNA by removing acetyl groups (O=C-CH3) from -N-acetyl lysine amino acids. This is significant because DNA is wrapped around histones and that acetylation and de-acetylation control how DNA is expressed. In contrast to histone acetyltransferase, it acts differently. Since non-histone proteins are also among their targets, HDAC proteins are now also referred to as lysine deacetylases (KDAC) in order to better reflect their mode of action. The histone deacetylases are members of the ancient protein superfamily known as the histone deacetylase superfamily, along with the acetylpolyamine amidohydrolases and the acetoin utilization proteins.
Structure | Cat No. | Product Name | CAS No. | Product Description |
---|---|---|---|---|
V0289 | Givinostat HCl monohydrate (ITF-2357; Gavinostat)) | 732302-99-7 | Givinostat (formerly ITF2357; Gavinostat)is a potent andorally bioavailable inhibitor of both class I and class II histone deacetylase (HDAC) with potential anticancer activity. | |
V78109 | GK444 | GK444 (Compound 15a) is an HDAC1/2 inhibitor (IC50= 100 and 92 nM for HDAC1/2, respectively). | ||
V78703 | GK718 | GK718 is an HDAC1/3 inhibitor (IC50= 259 and 139 nM, respectively). | ||
V79732 | HDAC-IN-47 | HDAC-IN-47 is an orally bioactive histone deacetylase (HDAC) inhibitor (antagonist) with IC50s of 19.75 nM (HDAC1), 5.63 nM (HDAC6), 40.27 nM (HDAC3), and 57.8 nM (HDAC2). | ||
V78726 | HDAC-IN-49 | HDAC-IN-49 is a potent, non-selective HDAC (HDAC) inhibitor (antagonist) with IC50s of 13 nM, 14 nM, 21 nM, 1880 nM and 10 nM for HDAC1, HDAC2, HDAC3, HDAC4 and HDAC6 respectively. | ||
V78539 | HDAC-IN-61 | HDAC-IN-61 (compound 12k) is an orally bioavailable HDAC inhibitor. | ||
V79734 | HDAC-IN-64 | HDAC-IN-64 (Compound 13) is an HDAC inhibitor. | ||
V78305 | HDAC-IN-65 | HDAC-IN-65 (compound 6) is a selective histone deacetylase (HDAC) inhibitor (antagonist) with IC50 of 2.5μM. | ||
V78616 | HDAC-IN-66 | HDAC-IN-66 (compound 2F) is a selective HDAC inhibitor and Pomalidomide analogue that effectively inhibits hematological tumor cells. | ||
V79722 | HDAC/CD13-IN-1 | HDAC/CD13-IN-1 (Compound 12) is an HDAC/CD13 inhibitor (IC50= 0.34 μM for hCD13, 0.53 μM for porcine CD13, and 0.03, 0.06, and 0.02 μM for HDAC1/2/3 respectively). | ||
V78660 | HDAC1 Degrader-1 | HDAC1 Degrader-1 (compound 1a) is an HDAC1 degrader with anti-cancer activity. | ||
V79025 | HDAC6-IN-14 | HDAC6-IN-14 is a selective HDAC6 (HDAC) inhibitor (antagonist) with IC50 of 42 nM. | ||
V79726 | HDAC6-IN-15 | HDAC6-IN-15 is a selective histone deacetylase 6 (HDAC6) inhibitor. | ||
V79285 | HDAC6-IN-16 | HDAC6-IN-16 (compound 5c) is a histone deacetylase 6 (HDAC6) inhibitor based on Quinazolin-4(3H)-One. | ||
V79488 | HDAC6-IN-17 | HDAC6-IN-17 (compound 5b) is a potent HDAC6 inhibitor (antagonist) with IC50s of 150 nM, 1400 nM and 2300 nM for HDAC6, HDAC8 and HDAC4 respectively. | ||
V80137 | HDAC6-IN-18 | HDAC6-IN-18 (Compound 4) is the first irreversible HDAC6 isoform-selective inhibitor (antagonist) with potent activity against multiple myeloma. | ||
V78754 | HDAC6-IN-19 | HDAC6-IN-19 (Compound 14g) is an HDAC6 inhibitor (IC50= 2.68 nM). | ||
V79153 | HDAC6-IN-22 | HDAC6-IN-22 (compound 30) is an inhibitor (blocker/antagonist) of HDAC6 with IC50 of 4.63 nM. | ||
V80190 | HDAC6-IN-23 | HDAC6-IN-23 (compound 9) is an orally bioactive HDAC6 inhibitor. | ||
V78962 | HDAC6-IN-24 | HDAC6-IN-24 (compound N1) is an inhibitor (blocker/antagonist) of HDAC6. |